Simvastatin Oral Suspension Particle Size Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Patients, especially the elderly, face difficulties in swallowing simvastatin tablets, leading to concerns about overdose and harm when tablets are crushed or opened, highlighting the need for a liquid form of the medication that maintains bioavailability and stability.
Innovation Solution
A suspension formulation of simvastatin with specific particle size characteristics (at least 90 wt % of particles less than 100 μm in diameter) is developed, including a suspending agent and preservative, suitable for oral administration, which is stable and bioavailable, and can be used to treat conditions like hypercholesterolaemia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If simvastatin is formulated as a solid tablet, then storage stability and manufacturing ease are improved, but patient compliance and safety deteriorate due to difficulty in swallowing and risks of crushing
Solution Approach 1:
The patent transforms the physical state of simvastatin from solid tablet to liquid suspension form. This parameter change fundamentally alters the administration method, allowing easy oral intake without swallowing difficulties while maintaining dosing precision through controlled particle size distribution (at least 90 wt% of particles less than 100 μm in diameter) and formulation composition.
2Ease of operation
If simvastatin tablets are crushed or opened to facilitate administration, then ease of administration is improved, but dosing accuracy and patient safety deteriorate due to overdose risks and loss of controlled release properties
Solution Approach 1:
The patent creates a liquid suspension that is inherently designed for direct administration without modification. The formulation includes specific components (suspending agent, preservative, flavoring) that maintain stability and dosing accuracy in liquid form, eliminating the need to crush or open tablets. Each dose can be precisely measured from the liquid suspension, ensuring reliability without compromising safety.
3Ease of operation
If simvastatin is converted to liquid form, then patient compliance and ease of administration are improved, but formulation complexity and stability requirements worsen
Solution Approach 1:
The patent formulates simvastatin as a composite liquid suspension containing multiple components: simvastatin particles (with controlled size distribution), suspending agent, preservative, and flavoring agent. Each component serves a specific function - the suspending agent maintains particle dispersion, the preservative ensures stability, and the flavoring improves palatability. This composite approach manages formulation complexity while achieving the desired liquid form for easy administration.
4Manufacturing precision
If simvastatin particle size is reduced to enhance dissolution and bioavailability, then drug absorption is improved, but suspension stability and manufacturing precision worsen
Solution Approach 1:
The patent optimizes the particle size parameter by specifying that at least 90 wt% of simvastatin particles must be less than 100 μm in diameter. This parameter change enhances dissolution and bioavailability while the suspending agent in the formulation compensates for potential stability issues, maintaining a balanced formulation that achieves both improved absorption and acceptable suspension stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The suspension provides effective and stable bioavailability of simvastatin, suitable for treating conditions such as myocardial infarction and angina, while minimizing the risks associated with crushing tablets, and is suitable for use in children and adults.
Implementation Method 1
at least 90 wt % of the particles of simvastatin are less than 100 μm in diameter
Data Source
AI summary
Aqueous suspensions for oral administration are disclosed that include simvastatin having a d90 of simvastatin particles of less than about 100 μm as the active agent. The aqueous suspension also includes simvastatin as about 20 mg to about 80 mg per 5 ml of the aqueous suspension, a suspending agent as about 20 mg to about 50 mg of the aqueous suspension, a wetting agent, an antimicrobial preservative, an antifoaming agent, water, and a buffering system providing the aqueous suspension with a pH of about 6.4 to about 7. Methods of making such a suspension and methods of treatments in orally administering the same are also disclosed.